Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis.
Yeon Sik Hong,Su Jin Moon,Young Bin Joo,Chan Hong Jeon,Mi La Cho,Ji Hyeon Ju,Hye Jwa Oh,Yu-Jung Heo,Sung Hwan Park,Ho-Youn Kim,Jun-Ki Min +10 more
Reads0
Chats0
TLDR
IL-33 is involved in the pathogenesis of RA and may reflect the degree of inflammation in patients with RA, and the levels of IL-33, sST2 and C-reactive protein decreased after conventional disease-modifying antirheumatic drugs treatment in 10 patients with treatment-naïve RA.Abstract:
The interleukin-33 (IL-33)/ST2 pathway has emerged as an intercellular signaling system that participates in antigen-allergen response, autoimmunity and fibrosis. It has been suggested that IL-33/ST2 signaling has been involved in the pathogenesis of rheumatoid arthritis (RA), because IL-33 and its receptor have been specifically mapped to RA synovium. The aim of this study was to determine the levels of IL-33 and sST2 in sera and synovial fluids in patients with RA. The serum level of IL-33 was significantly higher in patients with RA (294.9 ± 464.0 pg/mL) than in healthy controls (96.0 ± 236.9 pg/mL, P = 0.002). The synovial fluid level of IL-33 was significantly higher in RA patients than in osteoarthritis patients. The level of serum sST2 was higher in RA patients than in healthy controls (P = 0.042). A significant relationship was found between the levels of IL-33 and IL-1β (r = 0.311, P = 0.005), and IL-33 and IL-6 (r = 0.264, P = 0.017) in 81 RA patients. The levels of IL-33, sST2 and C-reactive protein decreased after conventional disease-modifying antirheumatic drugs treatment in 10 patients with treatment-naive RA. Conclusively, IL-33 is involved in the pathogenesis of RA and may reflect the degree of inflammation in patients with RA.read more
Citations
More filters
Journal ArticleDOI
Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis.
In Ah Choi,Sang Jin Lee,Won Park,Sung Hwan Park,Seung Cheol Shim,Han Joo Baek,Dae Hyun Yoo,Hyun Ah Kim,Soo Kon Lee,Yun Jong Lee,Young-Eun Park,Hoon Suk Cha,Eun Young Lee,Eun Bong Lee,Yeong Wook Song +14 more
TL;DR: Serum IL-33 levels in RA patients receiving tocilizumab therapy decreased significantly, particularly in ACR20 responders, and may be a useful marker for monitoring responses to tocilIZumab Therapy.
Journal ArticleDOI
Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis.
Liya Li,Honglin Zhu,Xiaoxia Zuo +2 more
TL;DR: This work reviews the available information and focuses on the pleiotropic expression and pathogenesis of IL-33 in systemic sclerosis, as well as the feasibility of using IL- 33 in clinical applications.
Journal ArticleDOI
IL-33/ST2 correlates with severity of haemorrhagic fever with renal syndrome and regulates the inflammatory response in Hantaan virus-infected endothelial cells.
TL;DR: In this article, the IL-33/ST2 axis regulates the immune response during Hantaan virus (HTNV) infection, and the results indicated that the IL33 acts as an initiator of the "cytokine storm" during HTNV infection, while sST2 can inhibit this process.
Journal ArticleDOI
IL33 in rheumatoid arthritis: potential contribution to pathogenesis.
TL;DR: It has been shown that the administration of interleukin-33 exacerbates collagen-induced arthritis in experimental models, and a positive correlation between cytokine concentrations in serum and synovial fluid of patients with rheumatoid arthritis and disease activity was found.
Journal ArticleDOI
Blockade of IL-33 signalling attenuates osteoarthritis.
Zengliang He,Yan Song,Yongxiang Yi,Fengzhuo Qiu,Junhua Wang,Junwei Li,Qingwen Jin,Pradeep Kumar Sacitharan +7 more
TL;DR: Osteoarthritis is the most common form of arthritis characterised by cartilage degradation, synovitis and pain and the critical unmet need is to find therapeutic targets to reduce both disease progression and pain.
References
More filters
Journal ArticleDOI
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
TL;DR: The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control subjects with rheumatic diseases other than RA (non-RA).
Journal Article
Revised criteria for the classification of rheumatoid arthritis.
TL;DR: The Bulletin on the Rheumatic Diseases has published all of the classification criteria for the rheumatic diseases to date, and these new revised classified criteria for rheumatoid arthritis are very important as they should provide understanding of the possibly changing face of rheumatism.
Journal ArticleDOI
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines
Jochen Schmitz,Alexander Owyang,Elizabeth R. Oldham,Yaoli Song,Erin Murphy,Terril K. McClanahan,Gerard Zurawski,Mehrdad M. Moshrefi,Jinzhong Qin,Xiaoxia Li,Daniel M. Gorman,J. Fernando Bazan,Robert A. Kastelein +12 more
TL;DR: A member of theIL-1 family, IL-33, which mediates its biological effects via IL-1 receptor ST 2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T( H)2 cells is reported.
Journal ArticleDOI
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
TL;DR: The current knowledge regarding the role of proinflammatory cytokines in the pathophysiology of OA is discussed and the potential of anticytokine therapy in the treatment of this disease is addressed.
Journal ArticleDOI
Disease-associated functions of IL-33: the new kid in the IL-1 family.
TL;DR: IL-33 is host-protective against helminth infection and reduces atherosclerosis by promoting TH2-type immune responses but can also promote the pathogenesis of asthma by expanding TH2 cells and mediate joint inflammation, atopic dermatitis and anaphylaxis by mast cell activation.